Abstract
Twenty-seven children and young adults with growth hormone deficiency (GHD) were given an i.v bolus of 200 ug of either GHRH(1-40) or of a shorter analogue of growth hormone-releasing hormone, GHRH(1-29)NH2; serum GH and somatomedin-C levels were measured. Thirteen showed a significant rise in serum GH, including 3 patients with hypothalamic tumours, 7 with idiopathic isolated GHD or panhypopituitarism and 3 children cranially-irradiated for non-endocrine tumours. A poor response was seen in patients with isolated GHD who had been on long-term therapy. Four patients given a second dose of 500 ug GHRH(1-29)NH2 two hours after the first dose showed little response to this second dose. Long-term (8-24 hr) i.v infusion of GHRH(1-29)NH2 demonstrated pulsatile GH secretions with no evidence of priming or down-regulation. Somatomedin-C levels, when measured, rose in parallel to serum GH, and often became normal. It is concluded (i) that children with idiopathic GHD, hypothalamic tumours, and cranial irradiation may have a defect in the synthesis or delivery of endogenous GHRH; (ii) GHRH(1-29)NH2 is a useful test for pituitary GH reserve in such patients; (iii) GHRH(1-29)NH2 may have long-term therapeutic potential.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grossman, A., Savage, M., Blacklay, A. et al. Responses of serum GH and somatomedin-C to an analogue of GHRH in children with growth hormone deficiency. Pediatr Res 18, 1206 (1984). https://doi.org/10.1203/00006450-198411000-00035
Issue Date:
DOI: https://doi.org/10.1203/00006450-198411000-00035